osilodrostat
Sign in to saveAlso known as LCI699, LCI-699
Osilodrostat, sold under the brand name Isturisa, is a medication used for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Osilodrostat is an orally active (taken by mouth), nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of 11beta-hydroxylase (CYP11B1).
Wikidata facts
- Mass
- 227.085876
Show 3 more facts
- chemical formula
- C₁₃H₁₀FN₃
- canonical SMILES
- C1CC2=CN=CN2C1C3=C(C=C(C=C3)C#N)F
- isomeric SMILES
- C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
via Wikidata · CC0
~5 min read
Article
8 sectionsContents
- History
- Society and culture
- Legal status
- Economics
- Research
- References
- Further reading
- External links
Osilodrostat, sold under the brand name Isturisa, is a medication used for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Osilodrostat is an orally active (taken by mouth), nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of 11beta-hydroxylase (CYP11B1).
The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention).